Orchard Therapeutics PLC -‘s Lock-Up Period Set To End on April 29th (NASDAQ:ORTX)
Orchard Therapeutics’ (NASDAQ:ORTX) lock-up period will end on Monday, April 29th. Orchard Therapeutics had issued 14,285,715 shares in its IPO on October 31st. The total size of the offering was $200,000,010 based on an initial share price of $14.00. After the expiration of Orchard Therapeutics’ lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
A number of equities research analysts have recently commented on the stock. Zacks Investment Research cut shares of Orchard Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 2nd. Wedbush reiterated an “outperform” rating and set a $25.00 price target on shares of Orchard Therapeutics in a report on Friday, March 22nd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Orchard Therapeutics presently has a consensus rating of “Buy” and an average price target of $23.40.
NASDAQ:ORTX opened at $17.79 on Monday. Orchard Therapeutics has a 52 week low of $8.65 and a 52 week high of $21.64. The company has a market cap of $1.53 billion and a PE ratio of -1.74.
Orchard Therapeutics Company Profile
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.
Recommended Story: How dollar cost averaging works
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.